Welcome to our dedicated page for Avita Medical news (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on Avita Medical stock.
News and updates on AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) focus on its role as a therapeutic acute wound care company centered on the RECELL System and related wound care technologies. Company news frequently highlights developments in thermal burn and trauma treatment, clinical evidence for its products, and regulatory milestones in key markets.
Investors following RCEL news can expect coverage of financial results, revenue updates, and capital structure actions such as credit agreements and equity placements, as disclosed in Form 8-K filings and press releases. AVITA Medical regularly reports quarterly and annual financial performance, adjustments to revenue outlook, and steps taken to align operating expenses with its growth priorities.
News flow also includes clinical and scientific updates. AVITA Medical has reported data presentations at medical conferences, including systematic reviews of peer-reviewed literature and real-world registry analyses supporting the RECELL System in acute wound treatment. These items describe outcomes such as reduced donor site burden, faster healing, shorter hospital stays, and favorable economic impact in burn care.
Regulatory and market access developments are another recurring theme. The company has announced CE Mark approval for RECELL GO under the EU Medical Device Regulation, regulatory clearances for RECELL in Europe, Australia, and Japan, and support from Australia’s Medical Services Advisory Committee for the use of autologous skin cell suspension prepared with RECELL in severe burns. Corporate governance updates, such as board appointments and executive transitions, are also disclosed through AVITA Medical’s news releases.
For readers tracking RCEL, this news stream provides insight into the company’s clinical progress, regulatory status, financial performance, and leadership changes, all of which shape its position in the acute wound care and medical device landscape.
AVITA Medical (NASDAQ: RCEL) presented two studies at the 2025 Southern Region Burn Conference reinforcing the RECELL System as a standard of care in acute wound treatment. A global systematic review of 99 studies (>8,000 patients, 13 countries) found RECELL reduces donor site size (up to 97.55%), achieves rapid wound closure comparable or superior to STSG, and shows favorable pain, aesthetic, and health-economic outcomes. A U.S. registry analysis (ABA Burn Care Quality Platform; >8,500 RECELL patients) reported a 36% shorter hospital stay (5.6 days; p<0.0001), 83% discharged home vs 70% for STSG, and estimated cost savings of >$42,000 per patient.
AVITA Medical (NASDAQ: RCEL) will report third quarter 2025 financial results after U.S. market close on Thursday, November 6, 2025. The company will host a conference call and webcast the same day at 1:30 p.m. Pacific Time (Friday, November 7, 2025 at 8:30 a.m. Australian Eastern Daylight Time) to discuss results and recent business highlights.
The live webcast will be available in the Events & Presentations section of AVITA Medical's investor website at ir.avitamedical.com. Telephone participants must register in advance to receive dial-in details and a personal PIN; a replay will be posted on the investor site shortly after the live event.
AVITA Medical (NASDAQ: RCEL) announced that Australia’s Medical Services Advisory Committee (MSAC) recommended amendments to the Medicare Benefits Schedule to include autologous skin cell suspension (ASCS) prepared with RECELL for severe acute burn wounds in adults and children.
MSAC concluded RECELL is as safe and effective as traditional autologous skin grafting and noted benefits including donor site sparing, reduced need for additional grafting, shorter hospital stays, less pain, and minimized scarring. Recommended uses include adults with ≥20% TBSA, pediatrics with ≥10% TBSA, and whole-of-face closure.
AVITA Medical (NASDAQ: RCEL) announced an immediate CEO transition: Board Chairman Cary Vance is named Interim CEO and will remain Chairman, while former CEO Jim Corbett is leaving the company. Board member Jan Stern Reed was appointed Lead Independent Director and the Board will engage a search firm to find a permanent CEO, considering internal and external candidates including Mr. Vance.
The Company expects preliminary Q3 2025 revenue of approximately $17 million. AVITA secured a waiver from OrbiMed for the Q3 2025 trailing 12-month net revenue covenant and is negotiating revised future covenants. An earnings call is scheduled for November 6, 2025.
AVITA Medical (NASDAQ: RCEL) announced that hospitals will now be eligible for New Technology Add-on Payment (NTAP) reimbursement from CMS when using RECELL to treat non-burn trauma and surgical full-thickness wounds. Starting October 1, 2025, hospitals can receive up to $4,875 in additional reimbursement per case through September 30, 2026.
The NTAP designation was granted under CMS's alternative pathway for FDA Breakthrough Devices. A clinical trial published in the Journal of Trauma and Acute Care Surgery demonstrated that RECELL achieved comparable wound closure while requiring 27% less donor skin compared to standard skin grafting. The technology prepares Spray-On Skin™ cells from a small sample of the patient's healthy skin.
AVITA Medical (NASDAQ: RCEL) has received CE Mark approval under the EU Medical Device Regulation for RECELL GO, enabling commercialization across Europe and other markets that recognize the CE Mark. RECELL GO is a point-of-care device that prepares Spray-On Skin™ Cells from a patient's own skin sample to promote healing in burns and traumatic or surgical wounds.
Recent data presented at the 2025 European Burns Association Congress showed that adults with deep partial-thickness burns treated with RECELL experienced a 36% reduction in hospital stays compared to traditional grafting. The company plans to begin commercialization in select European countries, including Germany, Italy, and the United Kingdom.
AVITA Medical (NASDAQ: RCEL) announced compelling real-world data demonstrating significant benefits of its RECELL® System in burn treatment. The analysis from the U.S. national burn registry showed that RECELL reduces hospital length of stay by 36% compared to traditional skin grafts in adults with deep second-degree burns.
The study of 741 adults revealed RECELL-treated patients experienced an average 5.6-day reduction in hospital stay, potentially saving over $42,000 per patient in costs. The system enables hospitals to treat 13 more patients per bed annually. RECELL requires 97.5% less skin compared to traditional grafts while improving donor site healing, pain, and scarring.
AVITA Medical (NASDAQ: RCEL) has announced its participation in three major investor conferences this September. The company's management will engage in the following events:
- Cantor Global Healthcare Conference on September 4, featuring a fireside chat with CFO David O'Toole
- Morgan Stanley Global Healthcare Conference on September 8, with CEO Jim Corbett
- Lake Street Capital Markets Best Ideas Growth Conference on September 11, with CFO David O'Toole
The Morgan Stanley fireside chat will be available via webcast for 90 days on AVITA Medical's investor relations website.
AVITA Medical (NASDAQ: RCEL) has successfully completed a private placement in Australia, raising approximately US$15 million (A$23 million) through the issuance of 17.2 million new CHESS Depositary Interests (CDIs). The placement was priced at A$1.32 per CDI, representing an 11% discount to the last closing price of A$1.48.
The funds will be utilized for working capital requirements and strategic flexibility to support the company's therapeutic acute wound portfolio growth. AVITA Medical expects this capital to sustain operations until it achieves free cash flow in 2026. The new CDIs are scheduled for settlement on August 19, 2025, with trading on the ASX commencing August 20, 2025.
AVITA Medical (NASDAQ: RCEL) has announced an upcoming investor webinar briefing scheduled for August 14, 2025, at 9 AM AEDT (August 13 at 4 PM PST). The presentation will feature CEO Jim Corbett and CFO David O'Toole, who will discuss the company's Q2 2025 financial and business results.
The webinar will include a Q&A session, with participants able to submit questions through the registration page. A replay will be made available on AVITA Medical's investor relations website after the event.